Immutep Limited

ASX:IMM.AX

0.28 (AUD) • At close November 5, 2024
Bedrijfsnaam Immutep Limited
Symbool IMM.AX
Munteenheid AUD
Prijs 0.28
Beurswaarde 407,279,600
Dividendpercentage 0%
52-weken bereik 0.23 - 0.485
Industrie Biotechnology
Sector Healthcare
CEO Mr. Marc Voigt
Website https://www.immutep.com

An error occurred while fetching data.

Over Immutep Limited

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy

Vergelijkbare Aandelen

Capitol Health Limited logo

Capitol Health Limited

CAJ.AX

0.36 AUD

Trajan Group Holdings Limited logo

Trajan Group Holdings Limited

TRJ.AX

1.155 AUD

Starpharma Holdings Limited logo

Starpharma Holdings Limited

SPL.AX

0.1 AUD

Cogstate Limited logo

Cogstate Limited

CGS.AX

0.975 AUD

AFT Pharmaceuticals Limited logo

AFT Pharmaceuticals Limited

AFP.AX

3.2 AUD

Aroa Biosurgery Limited logo

Aroa Biosurgery Limited

ARX.AX

0.56 AUD

Race Oncology Limited logo

Race Oncology Limited

RAC.AX

1.585 AUD

Paradigm Biopharmaceuticals Limited logo

Paradigm Biopharmaceuticals Limited

PAR.AX

0.22 AUD

Pacific Smiles Group Limited logo

Pacific Smiles Group Limited

PSQ.AX

1.83 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)